NR2C2 and prostate cancer: In CD133+ stem/progenitor cells of prostate cancer and CD133+ C4–2 prostate cancer cells, IL-1ra expressed by CD133+ cells mediates testicular nuclear receptor 4 (TR4)-induced drug resistance57.